BOO 1003
Alternative Names: BOO-1003Latest Information Update: 19 Mar 2025
At a glance
- Originator Boost Neuroscience
- Class Nootropics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cognition disorders
Most Recent Events
- 19 Mar 2025 Early research in Cognition disorders in USA (unspecified route), before March 2025 (Boost Neuroscience pipeline, March 2025)